Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GemOxDexR followed by Zevalin consolidation for relapsed aggressive CD20-positive B-cell non-Hodgkin lymphoma
2005-005216-24Phase 2Terminated
- Sponsor
- Saarland University
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan, rituximab, oxaliplatin, gemcitabine and dexamethasone in mature B-cell lymphoma, sponsored by Saarland University. Primary endpoint: Secondary complete remission rate. Started Oct 2006; status: terminated.
02
Drugs
ibritumomab tiuxetanrituximaboxaliplatingemcitabinedexamethasone
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2005-005216-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005216-24.